# NCT05122546 (NCT05122546)

> CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05122546
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: City of Hope Medical Center
- Conditions: Advanced Clear Cell Renal Cell Carcinoma; Advanced Papillary Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Clear Cell Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
- Interventions: Cabozantinib S-malate; Clostridium butyricum CBM 588 Probiotic Strain; Nivolumab
- Enrollment: 31
- Primary outcome: Change in Bifidobacterium composition of stool

## Indexed commentary on NCT05122546 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05122546